Edwards LifesciencesXSWX:EW +0.37%97 Net Current Asset Value is CHF4.41 as of Mar. 2026, which is 100% below its 10-year median of 76.74. GuruFocus rates XSWX:EW with a GF Score™ of 97/100 and a GF Value™ of CHF75.73. The stock has 5 warning signs investors should review. Among 567 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 82.72% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Edwards Lifesciences's net current asset value per share for the quarter that ended in Mar. 2026 was CHF4.41.
The historical rank and industry rank for Edwards Lifesciences's Net Current Asset Value or its related term are showing as below:
XSWX:EW'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.78 Med: 76.74 Max: 406.53
Current: 15.99
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Edwards Lifesciences was 406.53. The lowest was 11.78. And the median was 76.74.
XSWX:EW's Price-to-Net-Current-Asset-Value is ranked worse than 82.72% of 567
companies
in the Medical Devices & Instruments industry
Industry Median: 4.98
vs XSWX:EW: 15.99
Edwards Lifesciences (XSWX:EW) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Edwards Lifesciences Net Current Asset Value Related Terms
Edwards Lifesciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences Net Current Asset Value Chart
XSWX:EW vs DXCM, GEHC, BSX: Net Current Asset Value Comparison
For the Medical Devices subindustry, Edwards Lifesciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of CHF4.41 mean?
Edwards Lifesciences (XSWX:EW) has a Net Current Asset Value of CHF4.41 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Edwards Lifesciences and its competitors. This is 94% below median its historical median of 76.74. Over the past decade, Edwards Lifesciences' Net Current Asset Value has ranged from 11.78 to 406.53. According to the industry distribution chart, Edwards Lifesciences ranks #469 out of 567 companies in the Medical Devices & Instruments industry, placing it in the top 82.7%.
Is Edwards Lifesciences' Net Current Asset Value too high?
Edwards Lifesciences' current Net Current Asset Value of CHF4.41 is 94% below median its 10-year median of 76.74. Over the past 10 years, this metric has ranged from a low of 11.78 to a high of 406.53. Based on the distribution chart, Edwards Lifesciences ranks #469 out of 567 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Net Current Asset Value compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #469 out of 567 companies for Net Current Asset Value. This places Edwards Lifesciences in the lower half of its industry. The industry median Net Current Asset Value is 4.98. Historically, Edwards Lifesciences' own Net Current Asset Value has ranged from 11.78 to 406.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.98, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Net Current Asset Value is CHF4.41, which is 94% below median its own 10-year median of 76.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Net Current Asset Value of CHF4.41. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current Net Current Asset Value is CHF4.41, which is 94% below median its 10-year median of 76.74. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Net Current Asset Value is CHF4.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.
Key valuation signals for XSWX:EW:
Net Current Asset Value: CHF4.41 (94% below median its 10-year median of 76.74)
GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for XSWX:EW
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
